thisdrug what a medicine's name tells you

WHO naming stem · infix · 44 listed names

-ki(n)-

This page was written with AI.

target: interleukin

WHO's definition, quoted as written in the 2024 stem book

12 of 44 names appear in these lists: 12 in the US list (FDA Drugs@FDA) and 11 in the EU central list (EMA); 11 have national brands in at least one EU/EEA country.

Names only. This page is about -ki(n)- as a part of a name. It has nothing on uses, doses, side effects or interactions of any medicine that carries it, and nothing here is medical advice. Ask a pharmacist or doctor about the medicine itself.

Where it sits in a name

WHO writes the stem as -ki(n)-. It has 2 spellings or places: kin inside the name, with letters before and after it (…kin…); ki inside the name, with letters before and after it (…ki…).

Of the 44 names WHO lists under it, 6 carry kin inside the name, with letters before and after it, 38 carry ki inside the name, with letters before and after it.

All 44 names WHO lists under -ki(n)-

These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.

Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 12 of 44 names appear in these lists: 12 in the US list (FDA Drugs@FDA) and 11 in the EU central list (EMA); 11 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.

  1. abrezekimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  2. avizakimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  3. bermekimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  4. bimekizumab
    US brands: BIMZELX
    EU (central) brands: Bimzelx
  5. briakinumab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  6. camoteskimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  7. canakinumab
    US brands: ILARIS
    EU (central) brands: Ilaris
  8. cendakimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  9. cergutuzumab amunaleukin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  10. clazakizumab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  11. depemokimab
    US brands: EXDENSUR
    EU (central) brands: Exdensur
  12. ebdarokimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  13. eblasakimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  14. enokizumab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  15. etokimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  16. fezakinumab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  17. gevokizumab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  18. gumokimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  19. itepekimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  20. ixekizumab
    US brands: TALTZ
    EU (central) brands: Taltz
  21. lebrikizumab
    US brands: EBGLYSS
    EU (central) brands: Ebglyss
  22. lusvertikimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  23. lutikizumab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  24. manfidokimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  25. mirikizumab
    US brands: OMVOH
    EU (central) brands: Omvoh
  26. netakimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  27. olokizumab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  28. ordesekimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  29. perakizumab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  30. pivekimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  31. pivekimab sunirine
    US brands: DECNUPAZ
    EU (central) brands: none found
  32. risankizumab
    US brands: SKYRIZI
    EU (central) brands: Skyrizi
  33. romilkimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  34. secukinumab
    US brands: COSENTYX
    EU (central) brands: Cosentyx
  35. sonelokimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  36. tildrakizumab
    US brands: ILUMYA
    EU (central) brands: Ilumetri
  37. torudokimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  38. tozorakimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  39. tralokinumab
    US brands: ADBRY
    EU (central) brands: Adtralza
  40. tucotuzumab celmoleukin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  41. ustekinumab
    EU (central) brands: Fymskina, Imuldosa, Otulfi, Pyzchiva, Stelara, Steqeyma, Usgena, Usrenty, Usymro, Uzpruvo, Wezenla, Yesintek
    3 moreAbsimky (withdrawn), Eksunbi (withdrawn), Qoyvolma (withdrawn)
  42. vunakizumab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  43. xeligekimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  44. ziltivekimab
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)

US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.

EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.

EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.

Decode another name

Decoded

briakinumab

Listed INNCarries 2 WHO stems, most specific first: -ki(n)- …

  • -ki(n)-inside the nameWHO lists it hereWHO definition: target: interleukin
  • -mabend of the nameWHO lists it hereWHO definition: monoclonal antibodies (previous naming scheme)

“briakinumab” is an INN that WHO lists under -ki(n)-, -mab in the 2024 stem book.

The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.

Source and licence

The definition of -ki(n)- (Part II B) and the 44 names (Part IV, group (a)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .

Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.

Made with AI tools. · Privacy